IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
نویسندگان
چکیده
منابع مشابه
Iron Chelation Therapy in Thalassemia Syndromes
Transfusional hemosiderosis is a frequent complication in patients with transfusion dependent chronic diseases such as thalassemias and severe type of sickle cell diseases. As there are no physiological mechanisms to excrete the iron contained in transfused red cells (1 unit of blood contains approximately 200 mg of iron) the excess of iron is stored in various organs. Cardiomyopathy is the mos...
متن کاملIron Chelation Therapy in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic option for these patients, especially since the approval of oral iron chelators, which are easier to use...
متن کاملMyelodysplastic Syndromes and Iron Chelation Therapy
Over recent decades we have been fortunate to witness the advent of new technologies and of an expanded knowledge and application of chelation therapies to the benefit of patients with iron overload. However, extrapolation of learnings from thalassemia to the myelodysplastic syndromes (MDS) has resulted in a fragmented and uncoordinated clinical evidence base. We're therefore forced to change o...
متن کاملRole of Iron Chelation Therapy in Thalassemia Major.
iron chelating therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Although desferrioxamine (DFO) has been available for treating transfusional iron overload from the early 1960s, the era of modern and effective iron chelating therapy started only 20 years ago with the introduction of subcutaneous DFO infusions by portable pumps...
متن کاملIron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
Iron overload (IOL) due to increased intestinal iron absorption constitutes a major clinical problem in patients with non-transfusion-dependent thalassemia (NTDT), which is a cumulative process with advancing age. Current models for iron metabolism in patients with NTDT suggest that suppression of serum hepcidin leads to an increase in iron absorption and subsequent release of iron from the ret...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Mediterranean Journal of Hematology and Infectious Diseases
سال: 2009
ISSN: 2035-3006
DOI: 10.4084/mjhid.2009.0034